Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI) Mar 27, 2013
Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology Mar 21, 2013
FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping Mar 13, 2013
Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013 Mar 4, 2013
Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care Conference Feb 28, 2013
Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings Feb 7, 2013
